Plain-English translation of NCT05700877 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Type 2 Diabetes research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether screening for early heart disease in people with type 2 diabetes—using a special heart imaging scan—helps doctors give you the right amount of treatment. Some participants will receive dapagliflozin and semaglutide along with other heart-protective treatments if their scan shows early disease, while others may need less intensive treatment if their scan is normal.
People with type 2 diabetes have a higher risk of heart disease, but doctors don't always know who needs more aggressive treatment and who doesn't. This study wants to see if using heart imaging to identify risk—and then tailoring treatment to that risk—prevents heart attacks and other heart problems better than standard care.
You likely qualify if…
You likely don't qualify if…
You will have a heart imaging scan (CT scan) to measure calcium in your arteries, which shows your heart disease risk. Based on your results, you'll either receive the new medications plus lifestyle advice, or be advised to reduce your current treatments. You'll complete questionnaires about your quality of life and health, and researchers will track your health outcomes and costs over the study period to see if this personalized approach works better than standard care.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
Denmark